目的 探讨细胞蛋白激酶抑制剂Flavopiridol及蛋白酶抑制剂Bortezomib在体内抑制多发性骨髓瘤细胞U266的细胞增殖作用及其机制.方法 以不同浓度的Flavopiridol及Bortezomib分别、联合作用于U266细胞,用MTT法检测细胞增殖抑制作用.采用western blot法检测Bcl-2及Mcl-1表达变化;结果①Flavopiridol比Bortezomib对U266细胞增殖抑制作用更强,IC50值分别为52.5 nM,25 nM.②与单独用药相比,Flavopiridol联合Bortezomib作用于U266细胞,IC50值有明显的下降为17.5 nM.③Flavopiridol及Bortezomib给药前后,Bcl-2蛋白表达无变化,而Mcl-1蛋白表达明显下降.结论 Flavopiridol联合Bortezomib用药能在体内明显抑制多发性骨髓瘤细胞U266的生长,其机制主要是通过诱导细胞凋亡来抑制增殖.%Objective To discuss the protein kinase inhibitor Flavopiridol and proteasome inhibitor Bortezomi inhibirntion of multiple myeloma ceils U266 cell proliferation and its mechanism of action. Methods different concentrations ofrnFlavopiridol and /or Bortezomib, respectively,the effects of U266 cells proliferation was detected by MTT. By westernrnblot to detect the expression of Bcl-2 and Mcl-1,reareh the change of Bcl-xl,Mcl-1 while U266 was dealed with Flarnvopiridol and Bortezomib. Results ①Compared with Bortezomib and Flavopiridol more proliferation of U266 cells,rn(IC50:52.5 nM,25 nM). ②Compared with the drug alone,Flavopiridol and Bortezomib,while the role of U266 ceilsrnwith IC50 values significantly reduced(IC50:17.5 nM). ③Flavopiridol and Bortezomib before and after administration,rnthe Bcl-2 protein expression remained unchanged,while Mcl-1 protein expression was significantly decreased. Conclusionrn Flavopiridol and Bortezomib medication in the body significantly inhibited U266 growth of multiple myeloma cells,rnand its mechanism is mainly inhibition of proliferation by inducing apoptosis.
展开▼
